Bulletin
Investor Alert

The Wall Street Journal Archives | Email alerts

Aug. 18, 2021, 12:35 p.m. EDT

Florida and Texas are turning to antibody treatments as COVID-19 cases surge

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regeneron Pharmaceuticals Inc. (REGN)

or Cancel Already have a watchlist? Log In

By Joseph Walker

Doctors are increasingly turning to antibody drugs in a bid to keep hospitals from being overwhelmed by a surge of Covid-19 cases, a turnabout after months in which the treatments went mostly unused.

Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN +2.77% , the primary provider of the treatments, delivered 135,023 drug doses to U.S. healthcare providers last week, a ninefold increase from a month earlier, according to data shared by the company with The Wall Street Journal.

Regeneron estimates that as recently as June, fewer than 5% of high-risk patients were receiving treatment, before increasing recently to as much as 30%, said Chief Executive Leonard Schleifer in an interview. The drugs, which have been shown to prevent hospitalizations, are paid for by the federal government, and distributed to patients free of charge.

The uptick in demand is being driven by the surge of infections, especially in the southern U.S., where vaccination rates are relatively low. Some states, including Florida, Texas and Mississippi, have rushed to expand antibody-drug infusion centers and, in some cases, have allowed high-risk patients to receive treatment without seeing a doctor first.

An expanded version of this article appears on WSJ.com.

Popular stories from WSJ.com:

/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 592.15
+15.95 +2.77%
Volume: 845,301
Oct. 26, 2021 4:00p
P/E Ratio
10.63
Dividend Yield
N/A
Market Cap
$61.63 billion
Rev. per Employee
$931,393
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.